PwC Becomes Partner in Medicines Manufacturing Innovation Center

Pharmaceutical Technology Editors

PwC has teamed up with CPI on the Medicines Manufacturing Innovation Center to strengthen the UK’s position in advanced medicines manufacturing.

CPI announced the signing of an agreement with PwC, making the latter a partner in the Medicines Manufacturing Innovation Center collaboration. The partnership will use PwC’s global reach, expertise, and experience within the life sciences sector to benefit patients, drive economic growth, and help strengthen the United Kingdom’s global position in advanced medicines manufacturing innovations, CPI said in a Feb. 11, 2021 press release.

PwC will be joining founding partners CPI, the University of Strathclyde, GlaxoSmithKline, and AstraZeneca to address challenges and maximize technology opportunities within the pharmaceutical supply chain. The collaboration will implement projects meant to advance emergent and disruptive technologies. The program is part-funded by Innovate UK through the Industrial Strategy Challenge Fund and Scottish Enterprise, via the Scottish Government.

PwC’s contributions will include the increase of opportunities for business development through its global connectivity and brand authority and an evaluation of the marketplace for future technologies. The company will also act as a scout for new disruptive innovations, organizations, and global opportunities. In addition, PwC will develop market analysis and studies to communicate the value of current and future projects and demonstrate impact as well help seek funding from private investors, industry, and government.

“We are excited to join the team at the Medicines Manufacturing Innovation [Center] bringing PwC’s insights, experiences, and connections. We are confident that this collaboration will have a big impact on the future of pharmaceutical manufacturing,” said Johnathon Marshall, UK Pharma and Life Science Consulting lead at PwC, in the press release.

“[A] planned new facility in Renfrewshire is befitting of the strength and depth of the pharma and life sciences capabilities here in Scotland. We have a highly skilled team within our pharma and life sciences industry group, and we’re really excited to be embarking on this partnership with the Medicines Manufacturing Innovation [Center]. Looking at the cutting-edge advanced manufacturing capabilities that exist here, we see it as a very significant GDP [gross domestic product] growth area for the UK,” added Scott Lawson, a Glasgow-based director at PwC, in the press release.

“By partnering with PwC, the Medicines Manufacturing Innovation [Center] will be able to work smarter, better, and faster, ensuring more value to patients and the economy while advancing the UK’s already strong medicines manufacturing industry even further,” said Dave Tudor, managing director of the Medicines Manufacturing Innovation Center, Biologics and Quality at CPI, in the press release.

Source: CPI